Cameron G.,Cancer Therapy and Research Center |
Cameron G.,Canadian Blood and Marrow Transplant Group |
Tantiworawit A.,Cancer Therapy and Research Center |
Halpenny M.,Cbs Therapeutics, Inc. |
And 14 more authors.
Cytotherapy | Year: 2011
Background aims. The ability of hematopoietic progenitor cellsapheresis (HPC-A) that have been stored for many years after cryopreservation to reconstitute hematopoiesis following high-dose chemo/radiotherapy has not been well-documented. Methods. In this retrospective study, eight Canadian centers contributed data from 53 autologous stem cell transplants (ASCT) performed using HPC-A that had undergone long-term storage (>2 years, range 27 years) and 120 ASCT using HPC-A stored for <6 months (short-term storage). Results. The doses of nucleated and CD34+ cells per kilogram recipient weight were similar between the short- (mean ± SD, 4.7 ± 4.9 × 10 8 and 6.8 ± 4.3 × 106, respectively) and long- (4.0 ± 4.9 × 108 and 6.1 ± 3.4 × 106, respectively) term storage groups. The median days to neutrophils (absolute neutrophil count; ANC) >0.5 × 109/L (median 11 days for both short- and long-term storage) and platelets >20 × 109/L (median 12 and 11 for short- and long-term storage, respectively) post-ASCT were not significantly different between the two groups. When ASCT performed with <5 × 106/kg CD34+ cells was compared there was also no difference in ANC or platelet recovery (median 12 days for both after short-term storage, and 12 and 11 days, respectively, after long-term storage). Fourteen HPC-A products stored for >5 years also showed similar count recoveries as the entire long-term storage group (median 11 days for both ANC and platelets). Conclusions. Cryopreserved HPC-A can be stored for at least 5 years with no apparent loss in their ability to support hematopoietic reconstitution after high-dose chemotherapy. © 2011 Informa Healthcare.